Total
0
Shares
Althea Group (ASX:AGH) - CEO, Joshua Fegan
CEO, Joshua Fegan
Source: The Green Fund
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Althea (AGH) has launched a new range of 20-millilitre cannabis oil products
  • The Melbourne-based company is a global manufacturer, seller and distributor of pharmaceutical cannabis products and cannabis-based consumer-packaged goods
  • Compared to its 50 millilitre and 100 millilitre products, Althea’s smaller 20 millilitre dose is designed to promote flexibility in patients’ treatment
  • AGH says the new product will allow patients to trial whether the treatment is beneficial for them before they transition to a more economical, larger bottle
  • The company anticipates the new product size will help combat the cost barriers preventing some patients from trialling the treatment
  • At this stage, AGH will launch its “flexi” 20 millilitre product range in Australia only
  • Althea shares are down by 0.96 per cent, trading at 51.5 cents each

Althea (AGH) has launched a new range of 20-millilitre (ml) full-spectrum cannabis oil products.

Based in Melbourne, Althea is a global manufacturer, seller and distributor of pharmaceutical cannabis products and cannabis-based consumer-packaged goods.

The company says the new range — which carries the same trade names and formulations as its existing 50ml and 100ml products — will provide new cannabis patients with the option to trial the medication over the recommended two- or three-week titration period.

The smaller dose, it says, will promote flexibility in patients’ treatment, especially when initiating new patients and those suffering from intermittent illnesses.

In this way patients, together with their healthcare professional, can determine whether the treatment is beneficial for them before transitioning to a more economical, larger bottle.

Cost remains a key barrier for patients in Australia

According to Althea, although the demand for medicinal cannabis products continues to grow in Australia, the associated costs have prohibited many patients from trialling the treatment.

The company’s expanded product portfolio therefore aims to provide a lower entry point — thereby increasing patient acquisition.

Althea CEO Joshua Fegan said he understands that price remains a challenge for many potential new patients that want to trial medicinal cannabis for their conditions.

“We believe the launch of the new Althea ‘flexi’ 20ml cannabis oil range will be a great way to provide more access to patients via trial size products,” Joshua continued.

“This will, in turn, build confidence in our medicines and brand as we continue to be the first choice for a growing number of Australia’s medicinal cannabis patients.”

By the end of 2020, Althea had more than 12,000 patients in Australia, with the number of healthcare professionals prescribing its cannabis products more than doubling to 834 from the previous year.

At this stage, the company is set to launch its “flexi” 20ml product range in Australia only.

Althea shares are down slightly by 0.96 per cent, trading at 51.5 cents at 2:16 pm AEDT.

AGH by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug